Quantum X Is At the Forefront Of Science And Innovation
Quantum X is a parent company to MAA Global consisting of leading scientists, where we develop novel therapeutics and much more
Learn more about novel drug acquisition, as well as research and development services to excel in medicinal invention, learn more about our current project- HLADrvax, a novel vaccine and breakthrough for Rheumatoid Arthritis.
Whats HLADrvax?
At Quantum X, we are redefining the future of autoimmune care with HLADrvax—a novel therapeutic solution designed to both treat early-stage Rheumatoid Arthritis (RA) and potentially prevent its onset.
Currently in the research and development phase, HLADrvax leverages advanced biochemical and biological methodologies to address a critical unmet need in immunosuppressive disease treatment. Our innovative approach targets immune system regulation at its core, offering hope for millions affected by RA.
With HLADrvax, Quantum X is committed to closing the gap in autoimmune therapeutics—driving progress, promoting prevention, and improving lives.
Next-Generation Electronic & Cyber Disruption System
At the convergence of cyber warfare, electromagnetic dominance, and AI-driven systems, Ghost-Melter represents a paradigm shift in how high-consequence threats are detected, disrupted, and deactivated — remotely. Directed waveform disruption via adaptable EMP/HPM architecture, deployable across multiple platforms (aerial, terrestrial, orbital). Real-time predictive threat detection using advanced signal intelligence and satellite-linked behavioral analytics. Situations requiring non-kinetic, remote disabling of hostile high-value systems — prior to deployment or mid-operation — without physical contact or escalation.
